Seminars in Nuclear Medicine
Volume 34, Issue 2 , Pages 134-153 , April 2004

Update in PET imaging of nonsmall cell lung cancer

  • Eric M Rohren

      Affiliations

    • Department of Radiology, Mayo Clinic, Rochester, MN, USA
    • Corresponding Author InformationAddress reprint requests to Eric Rohren, MD, PhD, Department of Radiology, Mayo Clinic, Rochester, MN 55905 USA
    • ,
  • Val J Lowe

      Affiliations

    • Department of Radiology, Mayo Clinic, Rochester, MN, USA

References 

  1. Cancer Facts and Figures 2003, in American Cancer Society, Surveillance Research. Atlanta: American Cancer Society; 2003;
  2. Swensen SJ, Jett JR, Hartman TE, et al.  Lung cancer screening with CT (Mayo Clinic experience). Radiology. 2003;226:756–761
  3. Garg K, Keith RL, Byers T, et al.  Randomized controlled trial with low-dose spiral CT for lung cancer screening (feasibility study and preliminary results). Radiology. 2002;225:506–510
  4. Erasmus JJ, Connolly JE, McAdams HP, et al.  Solitary pulmonary nodules: Part I. Morphologic evaluation for differentiation of benign and malignant lesions. Radiographics. 2000;20:43–58
  5. Kubota K, Matsuzawa T, Fujiwara T, et al.  Differential diagnosis of lung tumor with positron emission tomography (a prospective study). J Nucl Med. 1990;31:1927–1932
  6. Duhaylongsod FG, Lowe VJ, Patz EJ, et al.  Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg. 1995;110:130–139
  7. Bury T, Dowlati A, Paulus P, et al.  Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Resp J. 1996;9:410–414
  8. Knight SB, Delbeke D, Stewart JR, et al.  Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. Chest. 1996;109:982–988
  9. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med. 1996;37:943–948
  10. Lowe VJ, Duhaylongsod FG, Patz EF, et al.  Pulmonary abnormalities and PET data analysis (A retrospective study). Radiology. 1997;202:435–439
  11. Lowe VJ, Fletcher JW, Gobar L, et al.  Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol. 1998;16:1075–1084
  12. Croft DR, Trapp J, Kernstine K, et al.  FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence. Lung Cancer. 2002;36:297–301
  13. Goo JM, Im JG, Do KH, et al.  Pulmonary tuberculoma evaluated by means of FDG PET (Findings in 10 cases). Radiology. 2000;216:117–121
  14. Wilkinson MD, Fulham MJ, McCaughan BC, et al.  Invasive aspergillosis mimicking stage IIIA non-small-cell lung cancer on FDG positron emission tomography. Clin Nucl Med. 2003;28:234–235
  15. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nuc Med. 1994;35:1647–1649
  16. Yap CS, Schiepers C, Fishbein MC, et al.  FDG-PET imaging in lung cancer (how sensitive is it for bronchoalveolar carcinoma?). Eur J Nucl Med Mol Im. 2002;29:1166–1173
  17. Erasmus JJ, McAdams HP, Patz EF, et al.  Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol. 1998;170:1369–1373
  18. Swensen SJ, Viggiano RW, Midthun DE, et al.  Lung nodule enhancement at CT (multicenter study). Radiology. 2000;214:73–80
  19. Tateishi U, Nishihara H, Tsukamoto E, et al.  Lung tumors evaluated with FDG-PET and dynamic CT (the relationship between vascular density and glucose metabolism). J Comp Assist Tomogr. 2002;26:185–190
  20. Brown RS, Leung JY, Kison PV, et al.  Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med. 1999;40:556–565
  21. Marom EM, Aloia TA, Moore MB, et al.  Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer. 2001;33:99–107
  22. Nathan MA, Mullan BP, Hartman TE. Characterization of the solitary pulmonary nodule 18F-FDG PET versus nodule enhancement CT. Eur J Nucl Med. 2003;30(Suppl 2):S151
  23. Marom EM, Sarvis S, Herndon JE, et al.  T1 lung cancers (sensitivity of diagnosis with fluorodeoxyglucose PET). Radiology. 2002;223:453–459
  24. Zhuang H, Pourdehnad M, Lambright ES, et al.  Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412–1417
  25. Matthies A, Hickeson M, Cuchiara A, et al.  Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med. 2002;43:871–875
  26. Demura Y, Tsuchida T, Ishizaki , et al.  18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med. 2003;44:540–548
  27. Erasmus JJ, McAdams HP, Rossi SE, et al.  FDG PET of pleural effusions in patients with non-small cell lung cancer. AJR Am J Roentgenol. 2000;175:245–249
  28. Gupta NC, Rogers JS, Graeber GM, et al.  Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest. 2002;122:1918–1924
  29. Murray JG, Erasmus JJ, Bahtiarian EA, et al.  Talc pleurodesis simulating pleural metastases on 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol. 1997;168:359–360
  30. Van Schil PE, Van HRH, Schoofs EL. The value of mediastinoscopy in preoperative staging of bronchogenic carcinoma. J Thorac Cardiovasc Surg. 1989;97:240–244
  31. Patterson GA, Ginsberg RJ, Poon PY, et al.  A prospective evaluation of magnetic resonance imaging, computed tomography, and mediastinoscopy in the preoperative assessment of mediastinal node status in bronchogenic carcinoma. J Thorac Cardiovasc Surg. 1987;94:679–684
  32. Wahl RL, Quint LE, Greenough RL, et al.  Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images (preliminary prospective evaluation). Radiology. 1994;191:371–377
  33. Patz EJ, Lowe VJ, Goodman PC, et al.  Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Chest. 1995;108:1617–1621
  34. Scott WJ, Schwabe JL, Gupta NC, et al.  Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose. The Members of the PET-Lung Tumor Study Group. Ann Thorac Surg. 1994;58:698–703
  35. Sasaki M, Ichiya Y, Kuwabara Y, et al.  The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer (A comparative study with X-ray computed tomography). Eur J Nucl Med. 1996;23:741–747
  36. Steinert HC, Hauser M, Allemann F, et al.  Non-small cell lung cancer (nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling). Radiology. 1997;202:441–446
  37. Sazon DA, Santiago SM, Soo HG, et al.  Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Resp Critical Care Med. 1996;153:417–421
  38. Valk PE, Pounds TR, Hopkins DM, et al.  Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg. 1995;60:1573–1581
  39. Vansteenkiste JF, Mortelmans LA. FDG-PET in the locoregional lymph node staging of non-small cell lung cancer (a comprehensive review of the leuven lung cancer group experience). Clin Pos Imaging. 1999;2:223–231
  40. Pieterman RM, van Putten JW, Meuzelaar JJ, et al.  Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343:254–261
  41. Lardinois D, Weder W, Hany T, et al.  Staging of non-small cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500–2507
  42. Griffeth LK, Rich KM, Dehdashti F, et al.  Brain metastases from non-central nervous system tumors (Evaluation with PET). Radiology. 1993;186:37–44
  43. Palm I, Hellwig D, Leutz M, et al.  Brain metastases of lung cancer (Diagnostic accuracy of positron emission tomography with fluorodeoxyglucose (FDG-PET)). Med Klin. 1999;94:224–227
  44. Rohren EM, Provenzale JM, Barboriak DP, et al.  Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology. 2003;226:181–187
  45. Boland GW, Goldberg MA, Lee MJ, et al.  Indeterminate adrenal mass in patients with cancer (evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose). Radiology. 1995;194:131–134
  46. Erasmus JJ, Patz EJ, McAdams HP, et al.  Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol. 1997;168:1357–1360
  47. Bury T, Barreto A, Daenen F, et al.  Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med. 1998;25:1244–1247
  48. Marom EM, McAdams HP, Erasmus JJ, et al.  Staging non-small cell lung cancer with whole-body PET. Radiology. 1999;212:803–809
  49. Bury T, Dowlati A, Paulus P, et al.  Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J. 1997;10:2529–2534
  50. Lewis P, Griffin S, Marsden P, et al.  Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet. 1994;344:1265–1266
  51. Frank A, Lefkowitz D, Jaeger S, et al.  Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Rad Oncol Biol Phys. 1995;32:1495–1512
  52. Lowe VJ, Hebert ME, Hawk TC, et al.  Chest wall FDG accumulation in serial FDG-PET images in patients being treated for bronchogenic carcinoma with radiation. J Nucl Med. 1994;35:76
  53. Mah K, Cladwell CB, Ung YC, et al.  The impact of (18)F-FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma (a prospective study). Int J Rad Oncol Biol Phys. 2002;52:339–350
  54. Erdi YE, Rosenzweig K, Erdi AK, et al.  Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiotherapy Oncol. 2002;62:51–60
  55. Jeong HJ, Min JJ, Park JM, et al.  Determination of the prognostic value of [18F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nuc Med Commun. 2002;23:865–870
  56. Ahuja V, Coleman RE, Herndon J, et al.  The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer. 1998;83:918–924
  57. Dhital K, Saunders CA, Seed PT, et al.  [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg. 2000;18:425–428
  58. Vesselle H, Grierson J, Muzi M, et al.  In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans (correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors). Clin Cancer Res. 2002;8:3315–3323
  59. Yasukawa T, Yoshikawa K, Aoyagi H, et al.  Usefulness of PET with 11C-methionine for the detection of hilar and mediastinal lymph node metastasis in lung cancer. J Nucl Med. 2000;41:283–290
  60. Hustinx R, Lemaire C, Jerusalem G, et al.  Whole-body tumor imaging using PET and 2–18F-fluoro-L-tyrosine (preliminary evaluation and comparison with 18F-FDG). J Nucl Med. 2003;44:533–539

PII: S0001-2998(03)00106-5

doi: 10.1053/j.semnuclmed.2003.12.004

Seminars in Nuclear Medicine
Volume 34, Issue 2 , Pages 134-153 , April 2004

Article Tools

* Image Usage & Resolution